Sending the company's shares tumbling 14 percent, the US health regulator has restricted exports from a plant owned by Indian generic drugmaker Wockhardt in the latest ban on its products.

An "import alert" means "detention without physical examination of drugs" from companies which have failed to meet so-called "good manufacturing practices" for drugs, the FDA said.
Wockhardt shares fell as much as 13.98 percent to a day's low of 406 rupees on the Bombay Stock Exchange on news of the new import restrictions.
The same factory has already been targeted by Britain's health regulator, which last month recalled five drugs made by the firm at the plant.
Wockhardt has faced a string of export restrictions this year at some of its other factories in India. They were imposed by British and US watchdogs, citing manufacturing concerns.
There was no immediate comment from the company.
Advertisements
India's pharma giant Ranbaxy, after facing a lengthy legal battle in the United States, was hit by a new setback in September.
Advertisements
Now three of Ranbaxy's plants have been hit by a ban on exports to the United States, its largest market.
Source-AFP